ClinicalTrials.gg
CompletedNCT03357627Updated Feb 8, 2023

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

A Phase 1 interventional study of TAK-659 and Venetoclax in Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse and Lymphoma, Follicular, sponsored by Calithera Biosciences, Inc. Completed at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Calithera Biosciences, Inc · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2021, 5 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States — 140 open to participants now, 255 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Enrollment
587th of 1,377
43 · median 35
Started
2018
with 47 others
Phase 1
528 of 1,599
47 open now
Registered
1,227th of 1,599
by date

Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 587th largest by enrollment of the 1,377 interventional ones that give a count, is one of 48 that started in 2018, is one of 528 in phase 1, and was the 1,227th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

140 of the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

135 more — sign in →

All 140 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination in participants with non-Hodgkin lymphoma (NHL) relapsed and/or refractory after at least 1 prior line of therapy and to evaluate safety and tolerability of TAK-659 and venetoclax when administered in combination.

Read the detailed description

The drugs being tested in this study are called TAK-659 and venetoclax. TAK-659 in combination with venetoclax is being tested to treat people who have advanced NHL after at least 1 prior line of therapy. This study will look at the safety data, pharmacokinetic (PK) data and any early anti-tumor activity observed.

The study will enroll approximately 53 participants.

  • TAK-659 and venetoclax doses will be escalated according to a Bayesian logistic regression model (BLRM) with overdose control escalation schema. TAK-659 60 mg + Venetoclax 400 mg is the starting dose.

Participants could also receive 40 mg, 60 mg, 80 mg or 100 mg TAK-659 during dose escalation and 200 mg, 400 mg, 800 mg, or 1200 mg of venetoclax.

Following dose escalation the safety and tolerability of the MTD/RP2D of the TAK-659+venetoclax combination will be further explored in two dose-safety expansion cohorts, Cohort A in participants with DLBCL and Cohort B in participants with FL.

All participants will be asked to take one tablet of TAK-659 on an empty stomach at least 1 hour before and no sooner than 2 hours after eating food and/or drinking fluids other than water. Venetoclax will be taken with a meal and water 2 hours after TAK-659 has been taken. No food or drink (except water) are allowed between TAK-659 and venetoclax. TAK-659 and venetoclax should be taken at the same time each day throughout the study.

This multi-center trial will be conducted in the United States, Canada and Europe. The overall time to participate in this study is 20 months or until disease progression, unacceptable toxicities, or withdrawal from study by participant. Participants will make multiple visits to the clinic, and will be followed for 28 days (+10) days after the last dose of TAK-659 or venetoclax or the start of subsequent alternative anticancer therapy to permit the detection of any delayed treatment-related AEs. For participants enrolled in either the dose escalation or safety expansion phases, the maximum duration of treatment will be 12 months unless, in the opinion of the investigator and with the agreement of the sponsor, the participant would derive benefit from continued therapy beyond 12 months. Participants enrolled in the safety expansion part who stop treatment for any reason other than disease progression will continue PFS follow-up every 2 months after the last dose of study drug for up to 6 months or until disease progression or the start of alternative therapy, whichever occurs first.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large B-cell, Diffuse
  • Lymphoma, Follicular

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For the Dose Escalation phase, participants must have confirmed diagnosis of advanced NHL of any histology (with the exception of participants with mantle cell lymphoma [MCL] or chronic lymphoma leukemia [CLL]).
  2. For the Safety Expansion phase, participants must have histologically confirmed diagnosis of advanced DLBCL or FL.
  3. Radiographically or clinically with greater than or equal to (>=) 1 target lesion per IWG criteria for malignant lymphoma.
  4. or relapsed after at least 1 for whom no effective standard therapy is available per investigator's assessment.

    o Participants who are either treatment-naive to, relapsed after, or refractory to ibrutinib, idelalisib, or any other B cell receptor (BCR) pathway inhibitors not directly targeting spleen tyrosine kinase (SYK) are allowed.

  5. (ECOG) performance status score of 0 or 1.
  6. of greater than 3 months.
  7. Suitable venous access for the study-required blood sampling that is, including PK and pharmacodynamic sampling.
  8. Recovered (that is, less than or equal to [\<=] Grade 1 toxicity) from the reversible effects of prior anticancer therapy.

Exclusion criteria

Exclusion Criteria:

  1. Central nervous system (CNS) lymphoma; active brain or , as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
  2. History of drug-induced pneumonitis requiring treatment with ; history of idiopathic pulmonary fibrosis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  3. Participants requires the use of warfarin (use in prophylactic doses [example, deep vein thrombosis prophylaxis]) is allowed.
  4. Prior exposure to targeted SYK inhibitors.
  5. History of a prior intolerable toxicity, in the opinion of the investigator from another B-cell lymphoma (BCL)-2 family protein inhibitor study.
  6. Participants who are after or refractory to regimens containing venetoclax or other BCL2 inhibitors.
  7. Systemic anticancer treatment (including agents) or radiotherapy less than 2 weeks before the first dose of study treatment (\<=4 weeks for large molecule agents; \<=8 weeks for cell-based therapy or anti-tumor vaccine), or not recovered from the reversible effects of prior anticancer therapy.
  8. Prior stem cell transplant (ASCT) within 6 months preceding Cycle 1 Day 1.
  9. Prior allogeneic stem cell transplant and/or chimeric antigen receptor T-cell therapy at any time.
  10. Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.
  11. Known (HIV) positive or HIV-related .
  12. Received a live viral vaccine within 6 months prior to the first dose of study drug.
  13. Use or consumption of:

    • Medications or supplements that are known to be strong or moderate Cytochrome P4503A () inhibitors or strong or moderate CYP3A inducers and/or P-glycoprotein (P-gp) inhibitors or inducers within 7 days or within 5 times the inhibitor or inducer half-life (whichever is longer) before the first dose of study drugs. In general, the use of these agents is not permitted during the study except in cases in which an adverse event (AE) must be managed during interruption of study drug dosing.
    • Food or beverages containing grapefruit, Seville oranges, or Star fruit within 5 days before the first dose of study drugs. Note that food and beverages containing grapefruit, Seville orange, or Star fruit are not permitted during the study.
    • Preparations containing St. John's wort within 7 days before the first dose of study drugs. Note that preparations containing St. John's wort are not permitted during the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Dose Escalation: TAK-659 + Venetoclax

    TAK-659 40, 60, 80, or 100 milligram (mg) (tablet, orally, once daily, up to 35 days in Cycle 1 or in different intermittent schedules \[7 days dosing followed by 7 days off or 14 days dosing followed by 7 days off or other intermittent dosing schedules\]) along with venetoclax 200, 400, 800 or 1200 mg (tablet, orally, once daily, up to 35 days in Cycle 1). After Cycle 1, TAK-659 and venetoclax will be administered once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant.

    Drug: TAK-659 · Drug: Venetoclax

  • Experimental
    Safety Expansion: Diffuse Large B-cell Lymphoma (DLBCL) Cohort

    TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.

    Drug: TAK-659 · Drug: Venetoclax

  • Experimental
    Safety Expansion: Follicular Lymphoma (FL) Cohort

    TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.

    Drug: TAK-659 · Drug: Venetoclax

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with a Dose Limiting Toxicity (DLT)

    Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), Version 5.0 DLT will be defined as any of the events specified in the protocol that are considered by the investigator to be at least possibly related to therapy with study medications and that occur within the first cycle.

    Time frame: Baseline up to 5 weeks

  2. Percentage of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs), Grade 3 or Higher Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Discontinuation

    AE Grades will be evaluated as per NCI CTCAE, version 5.0.

    Time frame: Baseline up to 13 months

Secondary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for TAK-659 and Venetoclax

    Time frame: Cycle 1 Days 1 and 21 or 28: Pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length is equal to [=] 35 days)

  2. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-659 and Venetoclax

    Time frame: Cycle 1 Days 1 and 21 or 28: Pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =35 days)

  3. AUCτ: Area Under the Plasma Concentration-time Curve from Time 0 to Time Over the Dosing Interval for TAK-659 and Venetoclax

    Time frame: Cycle 1 Days 1 and 21 or 28: Pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =35 days)

  4. Oral Clearance (CL/F) for TAK-659 and Venetoclax

    Time frame: Cycle 1 Days 1 and 21 or 28: Pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =35 days)

  5. Peak-trough Ratio (PTR) for TAK-659 and Venetoclax

    Time frame: Cycle 1 Days 1 and 21 or 28: Pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =35 days)

  6. Accumulation Ratio (Rac) for TAK-659 and Venetoclax

    Time frame: Cycle 1 Days 1 and 21 or 28: Pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =35 days)

  7. Trough Concentration (C trough) for TAK-659 and Venetoclax

    Time frame: Cycle 1 Days 1 and 21 or 28: Pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =35 days)

  8. Overall Response Rate (ORR)

    ORR is calculated as percentage of participants with complete response (CR) + percentage of participants with partial response (PR) as assessed by International Working Group (IWG) criteria for malignant lymphoma.

    Time frame: Up to 12 months

  9. Duration of Overall Response

    Time frame: Up to 12 months

  10. CR Rate

    CR rate is calculated as percentage of participants with CR as assessed by IWG criteria for malignant lymphoma.

    Time frame: Up to 12 months

  11. Duration of CR

    Time frame: Up to 12 months

  12. Time to Progression (TTP)

    TTP will be measured as the time in months from the first dose of study treatment to the date of the first documented disease progression as assessed using IWG criteria.

    Time frame: Up to 13 months

  13. Progression-free Survival (PFS)

    PFS is defined as the time from date of first study drug administration to the day of first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 18 months

07

Study locations

15 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • NorthShore Medical Group - Evanston
    Evanston, Illinois 60201, United States
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426, United States
  • Norton Cancer Institute - Shelbyville
    Shelbyville, Kentucky 40065, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Baylor Scott & White Research Institute
    Dallas, Texas 75246, United States
  • Hopital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Universitatsklinikum Heidelberg
    Heidelberg, Baden-wuerttemberg 69120, Germany
  • Universitatsklinikum Ulm
    Ulm, Baden-wuerttemberg 89081, Germany
  • Universitatklinikum der Ludwig-Maximilians-Universitat Munchen
    Munchen, Bayern 81377, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • Universitatsmedizin der Johannes Gutenberg Universitat
    Mainz, Rheinland-pfalz 55131, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Aug 2021, 41 months.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 41 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2017
First posted
Nov 30, 2017
StartActual
Feb 16, 2018
Primary completionActual
Aug 3, 2021
CompletionActual
Aug 3, 2021
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03357627
Responsible party
Sponsor
First posted
Nov 30, 2017
Start date
Feb 16, 2018
Primary completion
Aug 3, 2021
Completion
Aug 3, 2021
Last update
Feb 8, 2023

Study contacts

Medical Director
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-659

Start the discussion